IMMUNOPRECISE ANTIBODIES LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.25 USD | -2.34% |
|
+2.46% | -26.90% |
| Sales 2024 * | 24.59M 17.93M 1.43B | Sales 2025 * | 29.82M 21.74M 1.74B | Capitalization | 45.26M 33M 2.64B |
|---|---|---|---|---|---|
| Net income 2024 * | -12M -8.75M -699M | Net income 2025 * | -9M -6.56M -524M | EV / Sales 2024 * | 1.84 x |
| Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 1.52 x |
| P/E ratio 2024 * |
-3.56
x | P/E ratio 2025 * |
-4.83
x | Employees | 102 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 86.41% |
More Fundamentals
* Assessed data
More news
Latest transcript on ImmunoPrecise Antibodies Ltd.
More press releases
More news
| 1 day | -2.34% | ||
| 1 week | +2.46% | ||
| Current month | -2.34% | ||
| 1 month | -18.30% | ||
| 3 months | -33.86% | ||
| 6 months | -41.04% | ||
| Current year | -26.90% |
1 week
1.20
1.39
1 month
1.171.50
Current year
1.172.60
1 year
0.944.22
3 years
0.9416.47
5 years
0.9433.34
10 years
0.9433.34
| Managers | Title | Age | Since |
|---|---|---|---|
Jennifer Bath
CEO | Chief Executive Officer | - | 20/02/18 |
Kristin Taylor
DFI | Director of Finance/CFO | - | 28/09/23 |
Ilse Roodink
CTO | Chief Tech/Sci/R&D Officer | - | 30/06/21 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Mitchell Levine
CHM | Chairman | - | - |
Chris Buyse
BRD | Director/Board Member | 59 | 04/09/23 |
Jennifer Bath
CEO | Chief Executive Officer | - | 20/02/18 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 01/05/24 | 1.25 | -2.34% | 39,353 |
| 30/04/24 | 1.28 | -6.57% | 182,047 |
| 29/04/24 | 1.37 | +3.79% | 51,685 |
| 26/04/24 | 1.32 | +10.55% | 108,218 |
| 25/04/24 | 1.194 | -2.13% | 127,944 |
Delayed Quote Nasdaq, May 01, 2024 at 09:30 pm
More quotes
ImmunoPrecise Antibodies Ltd. is a Canada-based biotherapeutic research and technology company. It leverages systems biology, multiomics modelling and artificial intelligence systems to support its technologies in bioplatform-based antibody discovery. Its services include highly specialized, full-continuum therapeutic biologics discovery, development, and out-licensing to support its business partners to discover and develop novel biologics. It utilizes custom antigen modeling, target analysis using Natural Language Processing and the HYFTTM analysis to lay the groundwork for the subsequent experimental phases. It offers services, such as immunogen design and manufacturing, B cell sorting incorporating its function-first B cell screening and sequencing, and the production and screening of custom, immune, and naive phage display libraries. It also operates LSA instrument platform, which is a provider of high-throughput large and small molecule screening and characterization solutions.
Sector
Pharmaceuticals
Calendar
24/07/2024
- Q4 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
1.25
USD
Average target price
7
USD
Spread / Average Target
+460.00%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -26.90% | 32.89M | |
| -3.93% | 86.16B | |
| +2.76% | 40.17B | |
| -16.48% | 31.47B | |
| +55.51% | 25.24B | |
| -13.58% | 15.82B | |
| -9.12% | 11.96B | |
| -42.56% | 11.61B | |
| +5.77% | 8.84B | |
| -2.11% | 7.93B |
- Stock Market
- Equities
- IPA Stock
